Trials / Completed
CompletedNCT01003886
A Post Marketing Surveillance Study Of Doxazosin Mesylate GITS Among Filipino Patients With Benign Prostatic Hyperplasia (BPH)
A Post Marketing Surveillance Study To Determine The Safety, Tolerability And Effectiveness Of Doxazosin Mesylate GITS Among Filipino Adult Males With Benign Prostatic Hyperplasia (BPH)
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 989 (actual)
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc. · Industry
- Sex
- Male
- Age
- 18 Years – 90 Years
- Healthy volunteers
- Not accepted
Summary
This study aims to assess the safety, tolerability and efficacy of Doxazosin GITS in Filipino patients diagnosed with Benign Prostatic Hyperplasia (BPH) under the usual clinical care setting.
Detailed description
This is an open label study. All patients prescribed with Doxazosin GITS can be enrolled in this study.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Doxazosin mesylate GITS | Doxazosin mesylate GITS 4mg to 8mg once daily |
Timeline
- Start date
- 2009-05-01
- Primary completion
- 2011-01-01
- Completion
- 2011-01-01
- First posted
- 2009-10-29
- Last updated
- 2021-01-28
- Results posted
- 2011-10-28
Locations
67 sites across 1 country: Philippines
Source: ClinicalTrials.gov record NCT01003886. Inclusion in this directory is not an endorsement.